AKORN INC
LICENSE AND SUPPLY AGREEMENT
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>c89866exv10w1.htm
<DESCRIPTION>LICENSE AND SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="right" style="font-size: 10pt">EXHIBIT 10.1



<P align="center" style="font-size: 10pt"><B>LICENSE AND SUPPLY AGREEMENT</B>



<P align="left" style="font-size: 10pt"><B>Contents</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD>1.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Definitions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>2.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Rights</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Granting of Rights/ Warranties</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Negative covenants of LICENSEE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No duplication of Registration Dossiers</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>3.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">License Fee and Establishment Fees</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">License Fee</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Establishment and Maintenance Fee</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cost for Medical Commitments</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>4.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Regulatory Compliance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Marketing Authorization</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Maintenance of Marketing Authorization</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD>5.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Manufacture and Quality Assurance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Supply of Finished Product</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Complaints and Notifications</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Settlement of Complaints</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Responsibility</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>6.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Product Recall</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD>7.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Purchase and Delivery</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Exclusive Purchase</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Forecast</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Orders</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Minimum Order Quantities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">First Binding Order</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Order Confirmation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Quantity bulk batch Orders</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Delivery Time</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Delivery Conditions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Return of Finished Goods</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Tampering</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD>8.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Prices and Terms</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Initial Transfer Price</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Final Product Prices</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Payment</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Control of Total Gross Sales Price</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Right of HAMELN to terminate the Agreement</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Control on Base Cost</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>9.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Market Introduction and Marketing of the Product</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sales and Marketing Plan</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;Reserved&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Launch of Product</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Marketing of the Product</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Promotion</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Regular Reporting</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">Page 1 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Comply with Laws</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Stock Keeping</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trade Mark Protection</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>10.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Exchange of Information</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Serious Adverse Reactions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Not Serious Adverse Reactions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Other Information</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">11.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Confidentiality</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Confidential Information</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Disclosure of Confidential Information</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No confidentiality obligations</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>12.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Indemnification</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">12.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indemnification by HAMELN</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">12.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indemnification by LICENSEE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">12.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Insurance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">12.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Limitation of Liability</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD>13.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Relationship between Parties</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>14.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Effective Date and Duration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Term</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination upon Breach</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination upon Bankruptcy</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination by HAMELN</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Effect of Termination</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>15.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Rights and Obligations upon Termination</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">In case of Expiration or Regular Termination</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">In case of breach by HAMELN</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">In case of breach by LICENSEE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>16.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Protection of Licensed Patents</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD>17.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Patent Strategy, Judicial Cost and Legal Fees</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">17.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Patent Strategy</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">17.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Judicial Cost and Legal Fees</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>18.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Force Majeure</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD>19.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Severability</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>20.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Waiver</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD>21.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Notices</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>22.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Governing Law and Dispute Resolution</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">22.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governing Law</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">22.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dispute Resolution</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD>23.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Miscellaneous</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">23.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Entire Agreement</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">23.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Modifications</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">23.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Interpretation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">23.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Counterparts</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">23.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Severability</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">23.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Setoff</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">23.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assignments</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">23.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Interpretation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">23.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Special Clauses</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">Page 2 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt"><B>LICENSE AND SUPPLY AGREEMENT</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This LICENSE AND SUPPLY AGREEMENT is made and entered into this 11th day
of November&nbsp;2004, by and between HAMELN PHARMACEUTICALS GMBH, a company
organized and existing under the laws of Germany with its principal office at
Langes Feld 13, D-31789 Hameln, Germany (&#147;HAMELN&#148;), and AKORN, INC., a company
organized and existing under the laws of Louisiana with its principal office at
2500 Millbrook Drive, Buffalo Grove, Illinois 60089-4694, United States of
America (&#147;LICENSEE&#148;).


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, HAMELN has developed pharmaceutical specialties in different
pharmaceutical dosage forms and furthermore has compiled Registration Dossiers
for obtaining Marketing Authorizations for the Products in the Territory (all
as defined hereinafter);


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS HAMELN is seeking an exclusive distributor of the Products in the
Territory upon the general terms outlined in the DTPA Business Principles
executed by the Parties and attached hereto as Appendix&nbsp;A;


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS LICENSEE is interested in obtaining the exclusive use of the
Marketing Authorization for the Products in the Territory in order to
exclusively promote, market, sell and distribute the Products in the Territory;


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the mutual promises, covenants and
obligations contained herein, the receipt and sufficiency of which are hereby
acknowledged, the Parties hereby agree as follows:


<P align="left" style="font-size: 10pt"><B>1. Definitions</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following definitions relate to the wording of this Agreement. The
meaning and content of the below terms is set forth next to it.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Active Substance&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means active pharmaceutical ingredients of the Products.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Affiliated Company&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means any company or business entity controlled by, controlling or under common control with a
Party to this Agreement. For this purpose, &#147;control&#148; means the direct or indirect ownership of more
than fifty percent (50%)) of the voting stock of a company, or in the absence of ownership of more
than fifty percent (50%) of the voting stock of that company, the power, directly or indirectly, to
direct or cause the direction of the management and policies of such company.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Agreement&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means this License and Supply Agreement, together with all attached appendices, as they may be
amended or otherwise modified from time to time pursuant to this Agreement.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Base Cost&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the cost of the Active Substance plus the total cost of labor and overhead expenses required
in the purchase of starting materials, manufacture, testing, storing and delivery of the Finished
Product.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Bulk Finished Product&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means Product which has undergone all stages of production except blistering, final packaging and/or
labeling.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;c-GMP&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means current good manufacturing practice in both the EU and in the Territory.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Confidential Information&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means all confidential information of a Party relating to any designs, know-how, inventions,
technical data, ideas, uses, processes, methods, formulae, research and development activities, work
in process, or any scientific, engineering,</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">Page 3 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">manufacturing, marketing, business or financial information relating to the disclosing Party, its present or future products, sales,
suppliers, customers, employees, investors or business, whether in oral, written, graphic or electronic form disclosed by the
Parties prior to or during this Agreement (which is marked confidential or acknowledged as being confidential prior to disclosure).
If the Confidential Information is disclosed orally or visually, it shall be identified as such at the time of disclosure and
confirmed in writing by the disclosing Party within thirty (30)&nbsp;days of disclosure. Confidential Information shall also include any
other information in oral, written, graphic or electronic form which, given the circumstances surrounding such disclosure, would be
considered confidential. This Agreement shall be deemed Confidential Information. HAMELN&#146;s Confidential Information shall include
the total Registration Dossier including all Information around the Registration Dossier, Marketing Authorization, Orphan Drug
applications and Orphan Drug designations and the patents and patent applications in the name of, or granted to HAMELN that may
cover the Product and/or the Active Substance to the extent relevant for the Territory, all as set forth in Appendix&nbsp;C, attached
hereto and fully incorporated herein, as amended by the Parties from time to time.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Effective Date&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the date on which this Agreement is signed by the Parties.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Establishment Fees&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning given in Article&nbsp;3.2.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Final Product Price&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning given in Article&nbsp;8.2.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Finished Product&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means Bulk Finished Product which has undergone blistering, final packaging and/or labeling.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Incoterms&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the 2000 edition of the &#147;International Chamber of Commerce Official Rules for the
Interpretation of Trade Terms&#148;.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Intellectual Property Rights&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means all rights of ownership and the exclusive entitlement to claim ownership and/or
registration of exclusive rights created under or by copyright, moral rights, design
registration, patent registration, trade mark registration and all other exclusive rights in or
to intangible property and all other intellectual and industrial property rights, including
rights in present and future intangible property and rights in information, including know-how,
granted by law or equity from time to time under a law or otherwise in the Territory or any
other jurisdiction throughout the world.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;License Fee&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning given in Article&nbsp;3.1.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Local Currency&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">are the currencies officially being used in the countries of the Territory.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Marketing Authorization&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Zulassung nach AMG) in relation to a Product, is the grant of all necessary registrations,
permits, licenses, authorizations, approvals and notifications by the Relevant Regulatory
Authority in the Territory for the development, manufacturing, testing, labeling, importation,
storage, promotion, sale, distribution and use of that Product in such Territory.</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">Page 4 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Orphan Drug&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means a Product that has been designated by the United States Food and Drug Administration
pursuant to the Orphan Drug Act as a drug for a specified rare disease or condition.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Party/ Parties&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means LICENSEE or HAMELN as the context requires and &#147;Parties&#148; means both LICENSEE and HAMELN.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Product(s)&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means all finished dosage form products set forth in Appendix&nbsp;B-2, attached hereto and fully
incorporated herein, as amended by the Parties from time to time.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Initial Transfer Price&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the minimum transfer price which is payable by LICENSEE to HAMELN for the supply of
Products, in Finished Product form, and which is documented in Appendix&nbsp;B-2.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Registration Dossiers&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means any and all information, processes, techniques, and data relating to the Product that are
necessary to obtain a Marketing Authorization.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Relevant Regulatory Authority&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"> means in relation to a country or region in the Territory, the governmental authority, whether
federal, state or municipal, regulating the development, manufacturing, testing, labeling, importation, storage, promotion, sale,
distribution and use of Products and the grant of Marketing Authorizations in such a country or region.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;SPC&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the summary of product characteristics as disclosed to the FDA.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Territory&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the United States of America and Canada.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Third Parties&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means all other companies, including, without limitation, Affiliated Companies of the Parties,
which are not party to this Agreement.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Third Party Patents&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the patents and patent applications in the name of Third Parties that may cover the
Product and/or the Active Substance to the extent relevant for the Territory</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Total Gross Sales Price&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the gross sales amount actually received by LICENSEE less up to two percent (2%) in
customary business term discounts (e.g. 2% 10 net 30 or 2% 10 net 60) for the sale or other
disposition of Products during a given period of time, without any other deductions. For the
avoidance of doubt, the Total Gross Sales Price will be equal to the amount reported by LICENSEE
to the United States Securities and Exchange Commission as trade receivables arising out of the
sale of Products in accordance with United States GAAP standards.</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt"><B>2. Rights</B>



<P align="left" style="font-size: 10pt"><B>2.1 Granting of Rights/ Warranties</B>



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HAMELN hereby grants to LICENSEE, subject to the terms and
conditions of this Agreement, the exclusive right to use the
Marketing Authorization to promote, market, sell and distribute the
Products under HAMELN&#146;s trademark in the Territory. HAMELN shall
not sell Products to any other party in the Territory.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The holder of Marketing Authorization for the Products under
this Agreement shall be HAMELN. HAMELN warrants that the Products
shall conform with all approved specifications for manufacture and
testing, the package insert and</TD>
</TR>


</TABLE>

<P align="center" style="font-size: 10pt">Page 5 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SPC as set forth in the Registration Dossier and Marketing
Authorization and that it will manufacture the Products in
conformity with c-GMP, all applicable United States Food and Drug
Administration regulatory requirements, the procedures and
parameters set forth in this Agreement and generally accepted
professional standards. HAMELN further warrants that it shall only
manufacture Products in a facility that has been inspected and
approved by the United States Food and Drug Administration pursuant
to c-GMP</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HAMELN covenants that it shall keep the Product packaging
and instructions current and in English. HAMELN warrants that the
Products shall adapt the latest developments in science and
technology as soon as practicable.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt"><B>2.2 Negative covenants of LICENSEE</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LICENSEE shall not:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>use the Registration Dossiers for the purpose of applying
itself or through Third Parties for Marketing Authorization for the
Products in and for countries inside or outside the Territory; or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>actively promote the sale of the Product to customers having
their place of business in countries inside the Territory which
LICENSEE knows want to sell the Products themselves primarily
outside of the Territory; or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sell the Product to customers having no place of business in
countries inside the Territory; or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>maintain any distribution depot for the Product outside the
Territory; or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>grant sub-licenses under all or any of the rights granted to
LICENSEE under Article&nbsp;2.1 above; or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>challenge directly or indirectly the validity of HAMELN&#146;s
Intellectual Property Rights relating to the Product; or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(vii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>during the term of this Agreement, market, sell, distribute
or otherwise be interested in other products containing the Active
Substance or products that are functionally equivalent thereof; or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(viii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>enter into any transactions, either directly or indirectly, with
respect to the Products with Affiliated Companies unless such
transactions are on terms and conditions no less favorable than
would be reached in a comparable arm&#146;s-length transactions with a
third party that is not an Affiliated Company.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt"><B>2.3 No duplication of Registration Dossiers</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE is not allowed to provide a Third Party with any kind of
duplicate Registration Dossiers for the Product under this Agreement.
Furthermore, LICENSEE is not allowed to sell the Marketing Authorization,
the Registration Dossiers, or parts hereof, to any Third Party or provide
any Third Party with the Registration Dossiers in any other way without
the explicit prior written consent of HAMELN.


<P align="left" style="font-size: 10pt"><B>3. License Fee and Establishment Fees</B>



<P align="left" style="font-size: 10pt"><B>3.1 License Fee</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE will pay a non-refundable one-time license fee in the amount
specified in Appendix&nbsp;B-1, attached hereto and fully incorporated herein,
(&#147;License Fee&#148;), subject to Article&nbsp;15.2. The payment of the License Fee
will not reduce the amount of any other payment provided for in this
Agreement. The License Fee is due and payable within thirty (30)
calendar days after the Agreement has been signed by both Parties and
LICENSEE has received an invoice accordingly from HAMELN. If HAMELN has


<P align="center" style="font-size: 10pt">Page 6 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="margin-left:3%; font-size: 10pt">not received the License Fee in full in readily available funds within
thirty (30)&nbsp;calendar days after the Agreement has been signed by both
Parties, the Agreement will automatically terminate with no further
action by either Party and shall be considered null and void.


<P align="left" style="font-size: 10pt"><B>3.2 Establishment and Maintenance Fee</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall pay HAMELN for all amounts due to applicable governmental
authorities in connection with maintaining the Marketing Authorization
and Registration Dossier in the Territory (&#147;Establishment Fees&#148;) as
follows. Upon HAMELN&#146;s receipt of any invoices for Establishment Fees,
HAMELN shall immediately send such invoices to LICENSEE. LICENSEE shall,
promptly following its receipt of such invoices, pay HAMELN the amount
due for the Establishment Fees set forth in such invoices. HAMELN shall
promptly upon its receipt of payment of Establishment Fees from LICENSEE
pay the applicable governmental authorities such amounts and shall send
LICENSEE documentation confirming payment of such Establishment Fees.
LICENSEE reserves the right to perform on behalf of HAMELN with respect
to payment of such Establishment Fees should HAMELN fail to pay the
applicable governmental authorities in a timely manner following HAMELN&#146;s
receipt of payment therefor from LICENSEE and in such case only LICENSEE
shall be permitted to deduct the amount of duplicate Establishment Fees
paid from amounts otherwise due to HAMELN. Except for the case described
in the previous sentence, the payment of Establishment Fees shall not
reduce the amount of any other payment from LICENSEE to HAMELN provided
for in this Agreement. LICENSEE shall be responsible to apply with
applicable governmental authorities for any permitted refunds of
Establishment Fees and HAMELN shall assist LICENSEE with such
applications by providing all necessary information and executing any
required documentation. To the extent that HAMELN receives any refunds
of Establishment Fees at any time, it shall promptly pay LICENSEE the
amount received pursuant to such refund.


<P align="left" style="font-size: 10pt"><B>3.3 Cost for Medical Commitments</B>




<P align="left" style="margin-left:3%; font-size: 10pt">AKORN will pay up to Four Hundred Fifty Thousand Euros (&#128;450,000) of
costs relating to regulatory commitments for post-approval studies of the
Product and the pharmacokinetic study for inhalation therapy.


<P align="left" style="font-size: 10pt"><B>4. Regulatory Compliance</B>



<P align="left" style="font-size: 10pt"><B>4.1 Marketing Authorization</B>




<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN hereby warrants that, to the best of its knowledge, there is no
hindrance that precludes distribution and/or sale of the Products, such
as patents, industrial protective rights or other rights. HAMELN further
warrants, to the best of its knowledge, that (i)&nbsp;none of the Products nor
any of their elements, nor the use thereof, nor any of HAMELN&#146;s
manufacturing processes or methods employed or to be employed at HAMELN&#146;s
facility violate or will violate or infringe upon the Intellectual
Property Rights of any Third Party; and (ii)&nbsp;there is neither pending nor
threatened any claim, litigation or proceeding in any way contesting
HAMELN&#146;s rights to manufacture or supply any of the Products or attacking
the validity or enforcement of any HAMELN&#146;s Intellectual Property Rights
related to its manufacturing processes or methods.



<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall promptly inform HAMELN about relevant requirements
LICENSEE has knowledge of for obtaining and maintaining the necessary
Marketing Authorizations.


<P align="center" style="font-size: 10pt">Page 7 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN shall ensure that all artwork (leaflet, box and label) on all
printed packaging materials comply with all applicable regulatory
requirements in the Territory.


<P align="left" style="font-size: 10pt"><B>4.2 Maintenance of Marketing Authorization</B>




<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN warrants that it shall maintain and keep the Marketing
Authorization current, and that it shall inform LICENSEE in writing of
all relevant variations to the Marketing Authorizations.


<P align="left" style="font-size: 10pt"><B>5. Manufacture and Quality Assurance</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.1 Supply of Finished Product</B>



<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN shall supply the Product to LICENSEE as a Finished Product. HAMELN
warrants that the Product is manufactured according to all applicable
c-GMP rules and regulations and in accordance with the current EU and
United States laws and the processes and techniques laid down in the
Marketing Authorization. Any intended change of manufacturer of the
Product shall be approved by the Relevant Regulatory Authorities of the
Territory before the first supply of the Product from HAMELN to LICENSEE.
HAMELN further warrants (i)&nbsp;that the Products shall be free from defects
in workmanship and materials; (ii)&nbsp;that the Products shall meet their
applicable specifications set forth in the applicable Marketing
Authorization; and (iii)&nbsp;that, upon delivery of a Product and during such
time as such Product was under HAMELN&#146;s control, the Product shall not be
adulterated, misbranded, misused, contaminated, tampered with or
otherwise altered, mishandled, or subjected to negligence.



<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN shall supply Products to LICENSEE finally packed under
HAMELN &#180;s own trade name and logo.


<P align="left" style="font-size: 10pt"><B>5.2 Complaints and Notifications</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Any complaint regarding defects in quality apparent upon inspection
and/or shortfalls in quantities of the Product delivered by and
attributable to HAMELN shall be made in writing by LICENSEE to HAMELN
within thirty (30)&nbsp;days after delivery and LICENSEE shall simultaneously
send samples of such defective Product to HAMELN. If LICENSEE fails to
notify HAMELN within such period, LICENSEE shall be deemed to have
accepted the shipment. Notwithstanding the previous sentence, in case
LICENSEE becomes aware of any defects in quality in the Product at any
time, LICENSEE shall notify HAMELN without undue delay.


<P align="left" style="font-size: 10pt"><B>5.3 Settlement of Complaints</B>




<P align="left" style="margin-left:3%; font-size: 10pt">In cases of objections on the ground of defective quality, HAMELN shall
rework or replace at its own discretion the faulty Product as soon as
practicable and free of charge, but in no case longer than the normal
lead time for such Product. Shortfalls in quantities delivered and
quantitative deficiencies shall be made up free of charge. Parties agree
that in the event that HAMELN does not acknowledge the defect of such
Product which LICENSEE has found to be defective, the Parties shall
endeavor to settle such disagreement amicably and constructively between
themselves.



<P align="left" style="margin-left:3%; font-size: 10pt">In the event that the Parties fail to agree within four (4)&nbsp;weeks after
HAMELN&#146;s receipt of the notice of defects, the Parties agree to nominate
an independent, reputable laboratory, acceptable to both Parties, which
shall examine representative examples taken from such consignment, using
the methods of analysis laid down in the Registration Dossier or as
otherwise agreed upon by both Parties, and the result shall be binding on
both Parties. The charges for such examination shall be borne by the
Party not prevailing in such dispute.


<P align="center" style="font-size: 10pt">Page 8 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>5.4 Responsibility</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Except for HAMELN&#146;s obligations pursuant to Article&nbsp;12.1 below, HAMELN&#146;s
responsibility for defective Product supplied to LICENSEE hereunder is
limited to the replacement or rework mentioned in Article&nbsp;5.3 only.


<P align="left" style="font-size: 10pt"><B>6. Product Recall</B>




<P align="left" style="margin-left:3%; font-size: 10pt">If any Relevant Regulatory Authority recommends, requests or
requires the recall of any of the Products due to an act, omission or
breach by HAMELN with respect to its obligations, covenants or warranties
herein or HAMELN deems it necessary to initiate a voluntary recall of any
batch of Products due to an act, omission or breach by HAMELN with
respect to its obligations, covenants or warranties herein, HAMELN will
immediately notify LICENSEE of such recall and will consult with LICENSEE
regarding the timely compliance with all applicable regulations and
requirements pertaining to that recall. In the event of such a product
recall, HAMELN will reimburse LICENSEE (i)&nbsp;within fifteen (15)&nbsp;days of
such recall all amounts paid by LICENSEE for Product subject to the
recall; and (ii)&nbsp;within fifteen (15)&nbsp;days of LICENSEE&#146;s invoice together
with supporting documentation from the applicable wholesalers, all costs
incurred by LICENSEE with respect to wholesaler recall costs; and (iii)
within fifteen (15)&nbsp;days of LICENSEE&#146;s invoice, all other costs incurred
with respect to the administration and implementation of the recall,
including, but not limited to, (a)&nbsp;notification/approval of Relevant
Regulatory Authorities; (b)&nbsp;notification to Product distributors/agents
and customers and/or contractors; (c)&nbsp;market withdrawal or field
correction; (d)&nbsp;return/destruction of recalled Products; and (e)
reasonable legal costs.



<P align="left" style="margin-left:3%; font-size: 10pt">If any Relevant Regulatory Authority recommends, requests or
requires the recall of any of the Products due to an act, omission or
breach by LICENSEE with respect to its obligations, covenants or
warranties herein, LICENSEE will immediately notify HAMELN of such recall
and will consult with HAMELN regarding the timely compliance with all
applicable regulations and requirements pertaining to that recall. In
the event of such a product recall, LICENSEE will pay for all costs
incurred with respect to the administration and implementation of such
recall and LICENSEE will reimburse HAMELN within fifteen (15)&nbsp;days of
HAMELN&#146;s invoice, all costs incurred by HAMELN with respect to the
administration and implementation of the recall, including, but not
limited to, (a)&nbsp;notification/approval of Relevant Regulatory Authorities;
(b)&nbsp;notification to Product distributors/agents and customers and/or
contractors; (c)&nbsp;market withdrawal or field correction; (d)
return/destruction of recalled Products; and (e)&nbsp;reasonable legal costs.



<P align="left" style="margin-left:3%; font-size: 10pt">To the extent that a product recall is not clearly due to an act,
omission or breach by either Party with respect to its obligations,
covenants or warranties herein, then the Parties shall mutually discuss
and negotiate in good faith an equitable solution with respect to costs
related to the administration and implementation of the recall.



<P align="left" style="margin-left:3%; font-size: 10pt">Both Parties shall cooperate and use best efforts to minimize the costs
of any product recall.


<P align="left" style="font-size: 10pt"><B>7. Purchase and Delivery</B>



<P align="left" style="font-size: 10pt"><B>7.1 Exclusive Purchase</B>




<P align="left" style="margin-left:3%; font-size: 10pt">During the term of this Agreement, LICENSEE shall purchase all quantities
for the Product for the Territory exclusively from HAMELN and HAMELN
agrees to sell to LICENSEE such quantities of the Product as LICENSEE
shall order from HAMELN in accordance with the terms of this Agreement.


<P align="center" style="font-size: 10pt">Page 9 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>7.2 Forecast</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall on a monthly basis provide HAMELN with a rolling
non-binding twelve (12)&nbsp;month forecast of its requirements of the
Product. The first four (4)&nbsp;months of such rolling forecast shall
constitute firm and binding orders. Further the Parties agree that for
the subsequent three (3)&nbsp;months each forecast may not deviate from
previously provided forecasts for that period by more than twenty percent
(20%), whereas the following five (5)&nbsp;months shall be considered for
planning purposes only. LICENSEE and HAMELN shall liaise with one
another on a quarterly basis in developing the forecast to accommodate
for both sales and manufacturing requirements and concerns.


<P align="left" style="font-size: 10pt"><B>7.3 Orders</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall submit purchase orders to HAMELN in writing. All purchase
orders shall include:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the quantity of the Product to be purchased;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the requested delivery date(s); and</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any other information dictated by the circumstances of the order.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt"><B>7.4 Minimum Order Quantities</B>




<P align="left" style="margin-left:3%; font-size: 10pt">The minimum order quantities for the Products are noted in Appendix&nbsp;B-1.


<P align="left" style="font-size: 10pt"><B>7.5 First Binding Order</B>




<P align="left" style="margin-left:3%; font-size: 10pt">On the Effective Date, a first binding order for the Products shall be
issued by the LICENSEE. The quantity of this first order is documented in
Appendix&nbsp;B-1 and is included in the first forecast provided by LICENSEE.


<P align="left" style="font-size: 10pt"><B>7.6 Order Confirmation</B>




<P align="left" style="margin-left:3%; font-size: 10pt">No purchase order shall be binding on HAMELN until accepted in writing
with confirmation of the delivery date. HAMELN will reply to LICENSEE
with respect to purchase orders within five (5)&nbsp;business days of HAMELN&#146;s
receipt. The terms and conditions of this Agreement shall prevail if the
terms and conditions stated in HAMELN &#180;s acceptance of the order or in any
other communication of HAMELN relating to the order are inconsistent with
these terms and conditions. HAMELN will accept all purchase orders in
any month until accepted purchase orders, in the aggregate, are up to
twenty percent (20%) greater than the applicable quantity set forth in
LICENSEE&#146;s forecast, and will use commercially reasonable efforts to
accept all purchase orders in any month that, in the aggregate, are in
excess of twenty percent (20%) than the applicable quantity set forth in
LICENSEE&#146;s forecast.


<P align="left" style="font-size: 10pt"><B>7.7 Quantity bulk batch Orders</B>




<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN will always produce a complete bulk batch size of unlabelled
Product, in order to split the bulk batch in several varying size
Finished Product batches for LICENSEE.



<P align="left" style="margin-left:3%; font-size: 10pt">Due to this procedure, LICENSEE accepts to receive Finished Product
not older than six (6)&nbsp;months from the manufacturing date of the bulk
batch.


<P align="left" style="font-size: 10pt"><B>7.8 Delivery Time</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Delivery time is subject to the forecast provided by LICENSEE as
mentioned under Article&nbsp;7.2 and the availability of approved artwork at
the time of issuing the order. In


<P align="center" style="font-size: 10pt">Page 10 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="margin-left:3%; font-size: 10pt">the event HAMELN supplies the Product as Finished Product, the delivery
time shall be no later than one (1)&nbsp;month after LICENSEE&#146;s purchase order
date to the extent the applicable purchase order is anticipated by
LICENSEE&#146;s forecast; or no later than four (4)&nbsp;months after LICENSEE&#146;s
purchase order date, to the extent the applicable purchase order is not
anticipated by LICENSEE&#146;s forecast.


<P align="left" style="font-size: 10pt"><B>7.9 Delivery Conditions</B>




<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN shall deliver the Product Ex Works, as such term is defined in
Incoterms 2000.


<P align="left" style="font-size: 10pt"><B>7.10 Return of Finished Goods</B>




<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN will not accept any return of Products from LICENSEE or customers
or agents of LICENSEE unless agreed in writing or unless otherwise
required in this Agreement.


<P align="left" style="font-size: 10pt"><B>7.11 No Tampering</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall use its best efforts to protect the quality of the Product
while in the LICENSEE&#146;s control and possession. In furtherance of the
foregoing, LICENSEE shall not (i)&nbsp;tamper with or use the Product except
for the purpose of conducting reasonable tests; (ii)&nbsp;sell or dispose of
(other than by destruction after obtaining the prior written consent of
HAMELN) any Product that LICENSEE knows has become damaged, nor permit
the salvage thereof except by such means and in such manner as HAMELN may
authorize in writing; (iii)&nbsp;remove, destroy, alter, or otherwise tamper
with the trade dresses, trademarks, trade names, slogans, serial numbers
and/or labels affixed to the Products by HAMELN, in any way, except that
LICENSEE, with the prior written approval of HAMELN, may affix such
additional labels as may be necessary and required by applicable law.


<P align="left" style="font-size: 10pt"><B>8. Prices and Terms</B>



<P align="left" style="font-size: 10pt"><B>8.1 Initial Transfer Price</B>




<P align="left" style="margin-left:3%; font-size: 10pt">The initial
transfer price applicable for LICENSEE&#146;s Products purchases
from HAMELN (&#147;Initial Transfer Price&#148;) as of the Effective Date is set
forth in Appendix&nbsp;B-2. The Parties shall in October of each year agree
on a revised Initial Transfer Price to be applicable for
LICENSEE&#146;s
Products purchases from HAMELN during the following calendar year. The
revised Initial Transfer Price, when agreed to by the Parties, will be
documented by the Parties in a revised Appendix&nbsp;B-2 to the Agreement
signed by both Parties, provided that in no case shall the revised
Initial Transfer Price in any year increase more than ten percent (10%)
over the Initial Transfer Price in effect in the immediately preceding
calendar year.


<P align="left" style="font-size: 10pt"><B>8.2 Final Product Prices</B>




<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN shall supply the Products to LICENSEE in each calendar quarter
hereunder at prices which correspond to fifty percent (50%) of the Total
Gross Sales Price actually achieved in the market in such calendar
quarter (&#147;Final Product Price&#148;), but in no event shall the price of the
Product be less than the then applicable Initial Transfer Product Price
as specified in Appendix&nbsp;B-2.



<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall provide HAMELN with summary documentation of all
sales transactions of the Products in the previous calendar quarter no
later than the 15th calendar day following the close of each such
quarter.


<P align="center" style="font-size: 10pt">Page 11 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="margin-left:3%; font-size: 10pt">On delivery of each ordered batch, LICENSEE shall be invoiced with
the Initial Transfer Price as listed in the then applicable Appendix&nbsp;B-2.
At the end of every calendar quarter, HAMELN shall invoice LICENSEE
according to the following formula: Final Product Price less the number
of Products invoiced during such quarter times the then applicable
Initial Transfer Price. For the conversion from Local Currency into
Euro, the exchange rate listed in the Wall Street Journal for the last
day of the applicable quarter will be used. For reference purposes, a
sample calculation is attached hereto as Appendix&nbsp;D.



<P align="left" style="margin-left:3%; font-size: 10pt">The difference between the amounts already paid by LICENSEE to
HAMELN for a calendar quarter (i.e., the number of Products invoiced
during such quarter times the then applicable Initial Transfer Price),
and the Final Product Price achieved by LICENSEE for such calendar
quarter shall be paid by LICENSEE to HAMELN no later than thirty (30)
calendar days after each calendar quarter (i.e., the end of each January,
April, July and October during the term of this Agreement).


<P align="left" style="font-size: 10pt"><B>8.3 Payment</B>




<P align="left" style="margin-left:3%; font-size: 10pt">All payments to be made pursuant to this Agreement shall be in Euro. All
invoices will be issued in Euro.



<P align="left" style="margin-left:3%; font-size: 10pt">The terms of payment for Initial Transfer Price shall be thirty
percent (30%) on the date of order and the remainder within thirty (30)
days after date of invoice; which shall never be earlier than the date of
shipment of the corresponding Product.



<P align="left" style="margin-left:3%; font-size: 10pt">Payment shall be affected by bank transfer to an account designated
in writing by HAMELN to LICENSEE.


<P align="left" style="font-size: 10pt"><B>8.4 Control of Total Gross Sales Price</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE agrees, by request of HAMELN and upon reasonable notice period,
to permit an independent certified public accountant, selected by HAMELN
and to whom LICENSEE has no reasonable objections, to audit the sales
activities and specifically the Total Gross Sales Price and invoiced
units in respect of the Products and all other relevant information which
are necessary in the auditor &#180;s opinion to determine the correctness and
accuracy of the calculations on which the Final Product Prices are based,
provided that such audit must take place during LICENSEE&#146;s regular
business hours and shall not unreasonably interfere with LICENSEE&#146;s
business. Such audit shall be at the sole expense of HAMELN and the
certified public accountant shall be obligated to execute LICENSEE&#146;s
confidentiality agreement and to treat all LICENSEE information and
materials as confidential. If the audit reveals that LICENSEE
underreported aggregate Total Gross Sales Price to HAMELN for any quarter
by ten percent (10%) or more, then LICENSEE shall pay to HAMELN within
thirty (30)&nbsp;calendar days of HAMELN&#146;s invoice therefor the amount that
the corresponding corrected Final Product Price for such quarter was
underpaid with interest at a ten percent (10%) rate per annum from the
date such amount would have been otherwise due, and all reasonable costs
and expenses incurred by HAMELN in connection with such audit.


<P align="left" style="font-size: 10pt"><B>8.5 Right of HAMELN to terminate the Agreement</B>




<P align="left" style="margin-left:3%; font-size: 10pt">If in any full calendar year the Final Product Price of the Product does
not exceed on an average basis the Base Cost of the Product by at least
twenty-five percent (25%), HAMELN will be entitled to terminate the
Agreement upon giving a six (6)&nbsp;month prior written notification thereof
to LICENSEE.


<P align="center" style="font-size: 10pt">Page 12 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>8.6 Control on Base Cost</B>




<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN agrees, by request of LICENSEE and upon reasonable notice period,
to permit an independent certified public accountant, selected by
LICENSEE and to whom HAMELN has no reasonable objections, to audit the
Base Cost and other relevant information which are necessary in the
auditor&#146;s opinion to determine the correctness and accuracy of the
calculations on which the Base Cost is based, provided that such audit
must take place during HAMELN&#146;s regular business hours and shall not
unreasonably interfere with HAMELN&#146;s business. Such audit shall be at
the sole expense of LICENSEE and the certified public accountant shall be
obligated to execute HAMELN&#146;s confidentiality agreement and to treat all
HAMELN information and materials as confidential.


<P align="left" style="font-size: 10pt"><B>9. Market Introduction and Marketing of the Product</B>



<P align="left" style="font-size: 10pt"><B>9.1 Sales and Marketing Plan</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE will, as soon as practicable following the Effective Date
hereof, consult with HAMELN and will prepare and provide HAMELN with a
sales and marketing plan detailing the quantities of the Products to be
sold, which will meet the minimum order quantities for the Products are
noted in Appendix&nbsp;B-1, and the activities to be undertaken by LICENSEE
(the &#147;Sales and Marketing Plan&#148;) in the period beginning on the Effective
Date and ending on the last day of the following calendar year. In
October of each calendar year LICENSEE will consult with HAMELN and will
prepare and provide HAMELN with a revised Sales and Marketing Plan for
the following calendar year, which will meet the minimum order quantities
for the Products are noted in Appendix&nbsp;B-1.


<P align="left" style="font-size: 10pt"><B>9.2 &#091;Reserved&#093;</B>



<P align="left" style="font-size: 10pt"><B>9.3 Launch of Product</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall introduce the Product to the market in the Territory
within sixty (60)&nbsp;days, following the grant of the Marketing
Authorization and shall not unreasonably delay such introduction, subject
to shipment of sufficient quantities of Product by HAMELN.



<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE represents, warrants and undertakes to HAMELN that it will use
commercially reasonable efforts to cause its customers not to offer,
sell, deliver and/or distribute the Product outside the Territory.


<P align="left" style="font-size: 10pt"><B>9.4 Marketing of the Product</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall use commercially reasonable efforts to market the Product
in the Territory, at its own expense, and to:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>advertise and promote sales of the Product, using techniques
and methods which are customary in the pharmaceutical industry for
the marketing of pharmaceutical Product and to promote and advertise
the Product in the same manner as it promotes and advertises other
similar product which it manufactures or distributes;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>make and maintain regular and sufficient contact with present
and future customers of the Product;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>maintain such sales organization, facilities, personnel and
training as may be required to ensure fulfillment of its obligations
under this Agreement;</TD>
</TR>


</TABLE>

<P align="center" style="font-size: 10pt">Page 13 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>conduct its obligations under this Agreement in a manner that
will reflect favorably upon LICENSEE, HAMELN and the Product so as
to preserve the goodwill and customer&#146;s acceptance of the Products.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt"><B>9.5 Promotion</B>




<P align="left" style="margin-left:3%; font-size: 10pt">During the
term of this Agreement, LICENSEE shall promote HAMELN&#146;s
Products in the Territory in such a manner as best to achieve the agreed
goals as laid down in the applicable Sales and Marketing Plan. To the
extent LICENSEE fails to substantially comply with the requirements of
the Sales and Marketing Plan in two (2)&nbsp;successive calendar years, then
HAMELN may terminate this Agreement, following written notice to LICENSEE
detailing such non-compliance and LICENSEE&#146;s failure to cure such
non-compliance within three (3)&nbsp;months.


<P align="left" style="font-size: 10pt"><B>9.6 Regular Reporting</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE will prepare a quarterly marketing reporting detailing own
marketing activities, competitors&#146; activities and actions, prices of
competitor products etc. and send this report not later than the 15th day
of January, April, July and October respectively to HAMELN.


<P align="left" style="font-size: 10pt"><B>9.7 Comply with Laws</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall, at its sole expense, comply with any applicable federal,
state, and/or local laws, regulations or ordinances in the Territory and
shall obtain any licenses, registrations, permits, certifications,
approvals and/or other similar consents or authorizations of any federal,
state, and/or local government authorities, agencies or divisions
thereof, as may be required for it to meet its obligations in connection
with this Agreement, except for those obligations that HAMELN is
obligated to comply with under this Agreement. For the avoidance of
doubt, LICENSEE shall, to the extent desirable, obtain certification
and/or designation of the Products under the SAFETY Act of the Homeland
Security Act of 2002 (the &#147;SAFETY Act&#148;) prior to initiating any sales of
the Products in the Territory at its sole expense. LICENSEE shall keep
HAMELN apprised of its activities with respect to obtaining certification
and/or designation under the SAFETY Act.


<P align="left" style="font-size: 10pt"><B>9.8 Stock Keeping</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE will maintain a distribution center in the Territory. LICENSEE
shall keep at all times sufficient stocks of the Products equivalent to
three (3)&nbsp;months estimated sales in order to ensure a continuous supply
to the market and shall not repack or otherwise change the Products but
shall sell them in their original form and packs as delivered by HAMELN,
unless otherwise agreed in writing by HAMELN.


<P align="left" style="font-size: 10pt"><B>9.9 Trade Mark Protection</B>




<P align="left" style="margin-left:3%; font-size: 10pt">No right, title or interest in or to any of HAMELN&#146;s Intellectual
Property Rights relating to the Products shall pass to LICENSEE by virtue
of the activities contemplated under this Agreement or by virtue of any
other activity. LICENSEE shall exercise vigilance to detect any
limitations, infringements, or improper or wrongful use or suspected
infringements, improper or wrongful use, third-party claims, actions, and
proceedings of and with regard to any such Intellectual Property Rights
in the Territory and shall immediately notify HAMELN in writing of same.
LICENSEE shall exert every effort to safeguard HAMELN&#146;s Intellectual
Property Rights in the Territory. LICENSEE shall fully cooperate with
HAMELN in any action HAMELN may take in order to prevent or end such
infringement, or improper or wrongful use or suspected infringement, or
improper or wrongful use. At HAMELN&#146;s request and expense, LICENSEE
shall assist HAMELN in defending any claim of infringement.


<P align="center" style="font-size: 10pt">Page 14 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>10. Exchange of Information</B>



<P align="left" style="font-size: 10pt"><B>10.1 Serious Adverse Reactions</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Both Parties shall report to each other promptly any information on
serious (expected or unexpected) adverse reactions attributable to the
use of the Product.


<P align="left" style="font-size: 10pt"><B>10.2 Not Serious Adverse Reactions</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Additionally, information on not serious adverse reactions attributable
to the use of the Product shall be reported to each other as soon as
practicable.


<P align="left" style="font-size: 10pt"><B>10.3 Other Information</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall report to HAMELN any information that is relevant in the
course of trade, or in the context of the Agreement. Should it be
required, further details regarding exchange of information will be
agreed to between the Parties and described in the technical agreement
and/or the pharmacovigilance agreement that the Parties may enter into.


<P align="left" style="font-size: 10pt"><B>11. Confidentiality</B>



<P align="left" style="font-size: 10pt"><B>11.1 Confidential Information</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Each Party (i)&nbsp;shall keep the other Party&#146;s Confidential Information
confidential and shall not directly or indirectly, use, divulge, publish
or otherwise disclose or allow to be disclosed any aspect of such other
Party&#146;s Confidential Information, except with the other Party&#146;s prior
written consent and as specifically permitted by this Agreement; and (ii)
shall refrain from any action or conduct which might reasonably or
foreseeably be expected to compromise the confidentiality or proprietary
nature of Confidential Information. Upon request, each of the Parties
shall immediately return to the other the originals and all copies of any
Confidential Information of the other Party. Each Party may disclose the
other Party&#146;s Confidential Information to the appropriate governmental
authorities in the Territory necessary to effectuate the purposes of this
Agreement. Each Party may additionally disclose and publish this
Agreement and the other Party&#146;s Confidential Information to the extent
required by applicable securities laws; provided that such disclosing
Party will endeavor to minimize the amount of such required disclosures
so as to avoid disclosing trade secrets.


<P align="left" style="font-size: 10pt"><B>11.2 Disclosure of Confidential Information</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Each Party may disclose the other Party&#146;s Confidential Information to
such of its directors, officers, employees and agents who need to know
the Confidential Information for the purposes hereunder and who are bound
by an agreement with the Party intending to disclose such Confidential
Information to them to keep such Confidential Information confidential.


<P align="left" style="font-size: 10pt"><B>11.3 No confidentiality obligations</B>




<P align="left" style="margin-left:3%; font-size: 10pt">A Party&#146;s obligations under Article&nbsp;11.1 above shall not apply to
information which such Party can show:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at the time of disclosure to be in the public domain; or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>after the time of disclosure becomes part of the public
domain by publication or otherwise, other than by an unauthorized
act or omission of such Party; or</TD>
</TR>


</TABLE>

<P align="center" style="font-size: 10pt">Page 15 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>was in such Party&#146;s rightful possession prior to the time of
disclosure and was not acquired directly or indirectly from the
disclosing Party, or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>is disclosed to such Party after the Effective Date by a
Third Party who did not acquire the Information from the disclosing
Party; or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>is independently developed by or for a receiving Party
completely apart from the disclosures hereunder.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt"><B>12. Indemnification</B>



<P align="left" style="font-size: 10pt"><B>12.1 Indemnification by HAMELN</B>




<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN shall indemnify, defend and hold harmless LICENSEE against all
damages, claims, liabilities, losses and other expenses, including,
without limitation, reasonable attorneys&#146; fees and costs, whether or not
a lawsuit or other proceeding is filed, that arise out of or relate to
(i)&nbsp;any dispute or claim that the Products, or any HAMELN manufacturing
processes or methods employed or to be employed, infringe or violate any
Third Party&#146;s Intellectual Property Rights; (ii)&nbsp;product liability
claims, injury to or death of persons or damage to property that may have
been caused, or that may be alleged to have been caused, directly or
indirectly, by HAMELN, the Products, or any HAMELN manufacturing
processes or methods employed or to be employed, HAMELN&#146;s employees or
agents, or HAMELN&#146;s Affiliated Companies, subcontractors, their employees
or agents; (iii)&nbsp;any defect in the Products, their manufacture, or other
failure of the Products to comply with their respective specifications,
the Marketing Authorization and/or Registration Dossiers, including, but
not limited to, any costs associated with Product recalls which directly
result from HAMELN&#146;s or HAMELN&#146;s Affiliated Companies&#146;, or their
respective subcontractors&#146;, employees&#146; or agents&#146; negligent acts or
omissions; (iv)&nbsp;any negligent act or omission of HAMELN, its agents, or
subcontractors; (v)&nbsp;a breach of any covenants or warranties provided by
HAMELN under this Agreement; or (vi)&nbsp;HAMELN&#146;s failure to fully conform to
all laws, ordinances, rules and regulations which affect the Products,
their use, or any part thereof. In the event HAMELN fails to promptly
indemnify and defend such claims and/or pay LICENSEE&#146;s expenses, as
provided above, LICENSEE shall have the right to defend itself and shall
have the right to withhold payments otherwise due to HAMELN to pay for
costs and expenses actually incurred by LICENSEE under this Article, and
in addition, HAMELN shall reimburse LICENSEE for any remaining reasonable
attorneys&#146; fees, costs and damages incurred in settling or defending such
claims within thirty (30)&nbsp;calendar days of each of LICENSEE&#146; written
requests, provided that any settlement shall only be with HAMELN&#146;s prior
written approval.


<P align="left" style="font-size: 10pt"><B>12.2 Indemnification by LICENSEE</B>




<P align="left" style="margin-left:3%; font-size: 10pt">LICENSEE shall indemnify, defend and hold harmless HAMELN against all
damages, claims, liabilities, losses and other expenses, including,
without limitation, reasonable attorneys&#146; fees and costs, whether or not
a lawsuit or other proceeding is filed, that arise out of or relate to
(i)&nbsp;any negligent act or omission of LICENSEE, its employees, its agents,
its Affiliated Companies, its subcontractors and their employees or
agents; and (ii)&nbsp;LICENSEE&#146;s breach of any covenants or warranties
provided by LICENSEE under this Agreement. In the event LICENSEE fails
to promptly indemnify and defend such claims and/or pay HAMELN&#146;s
expenses, as provided above, HAMELN shall have the right to defend
itself, and in that case, LICENSEE shall reimburse HAMELN for all of its
reasonable attorneys&#146; fees, costs and damages incurred in settling or
defending such claims within thirty (30)&nbsp;calendar days of each of
HAMELN&#146;s written requests, provided that any settlement shall only be
with LICENSEE&#146;s prior written approval.


<P align="center" style="font-size: 10pt">Page 16 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>12.3 Insurance</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Each Party shall obtain, at its expense, property, commercial and
liability insurance covering its obligations hereunder, in each case in
amounts appropriate to the conduct of its business, as determined in its
sole and exclusive judgment. The policies of insurance obtained by the
Parties hereunder must state that the insurer shall notify the other
Party at least thirty (30)&nbsp;days prior to termination, cancellation of, or
any material change in, the coverage provided. Each Party shall make
available to the other Party at such other Party&#146;s request certificates
of insurance evidencing satisfaction of its obligations under this
Article&nbsp;12.3.


<P align="left" style="font-size: 10pt"><B>12.4 Limitation of Liability</B>




<P align="left" style="margin-left:3%; font-size: 10pt">UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE FOR THE OTHER PARTY&#146;S
INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES,
INCLUDING LOSS OF PROFITS, WHETHER FORSEEABLE OR NOT, ARISING IN
CONNECTION WITH THIS AGREEMENT OR WITH THE USE OR LIABILITY TO USE THE
PRODUCTS FURNISHED UNDER THIS AGREEMENT. THE PREVIOUS SENTENCE SHALL NOT
LIMIT THE RESPECTIVE PARTIES&#146; INDEMNIFICATION OBLIGATIONS PURSUANT TO
ARTICLES 12.1 AND 12.2 TO THE EXTENT THAT SUCH DAMAGES ARE AWARDED TO
THIRD PARTIES AND WHICH ONE OF THE PARTIES HERETO IS OBLIGATED TO PAY.


<P align="left" style="font-size: 10pt"><B>13. Relationship between Parties</B>




<P align="left" style="margin-left:3%; font-size: 10pt">The relationship between the Parties under this Agreement is that of
independent contractors are not by this Agreement made agents or
employees of the other.


<P align="left" style="font-size: 10pt"><B>14. Effective Date and Duration</B>



<P align="left" style="font-size: 10pt"><B>14.1 Term</B>




<P align="left" style="margin-left:3%; font-size: 10pt">This Agreement shall be effective from the Effective Date and shall,
unless terminated earlier under the provisions of this Agreement,
continue for an initial term of five (5)&nbsp;years and thereafter extend
automatically for successive two (2)&nbsp;year periods. Unless otherwise
provided for herein, either Party may terminate this Agreement by giving
written notice to the other Party at least six (6)&nbsp;months prior to the
end of the initial five (5)&nbsp;years or the end of a successive two (2)&nbsp;year
term.


<P align="left" style="font-size: 10pt"><B>14.2 Termination upon Breach</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Unless otherwise provided for herein, if one Party materially breaches
any of the material terms of this Agreement and fails to remedy such
breach within sixty (60)&nbsp;days after the other Party has given notice
requiring it to do so, the non-breaching Party shall have the right to
terminate this Agreement upon one (1)&nbsp;months&#146; prior written notice. For
the purpose of this Agreement, non-compliance with payment obligations
under this Agreement will be considered a material breach of a material
term.


<P align="left" style="font-size: 10pt"><B>14.3 Termination upon Bankruptcy</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Either Party shall be entitled to terminate this Agreement immediately in
case a proceeding of bankruptcy or composition shall be instituted
against the other Party which is not dismissed within sixty (60)&nbsp;days, or
if an interim order is applied for or made, or a voluntary arrangement
approved, or if a petition for a bankruptcy order is presented or a
bankruptcy order is made against either Party or if a receiver or trustee


<P align="center" style="font-size: 10pt">Page 17 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="margin-left:3%; font-size: 10pt">in bankruptcy is appointed over either Party&#146;s estate or a voluntary
arrangement is proposed or approved or an administration order is made,
or a receiver or administrative receiver is appointed over any of either
Party&#146;s assets or undertaking or a winding up resolution or petition is
passed or presented (otherwise than for the purposes of a reconstruction
or amalgamation) or if any circumstances arise which would entitle the
court or a creditor to appoint a receiver, administrative receiver or
administrator or to present a winding-up petition or make a winding-up
order or other similar or equivalent action is taken against or by either
Party by reason of its insolvency or in consequence of debt.


<P align="left" style="font-size: 10pt"><B>14.4 Termination by HAMELN</B>



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HAMELN shall have the right to terminate this Agreement
immediately if LICENSEE challenges the validity of HAMELN&#146;s
Intellectual Property Rights that may apply to the Product, the
Active Substance or the manufacturing thereof.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HAMELN shall have the right to terminate this Agreement in
accordance with Articles 8.5 and 9.5.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HAMELN shall have the right to terminate this Agreement
immediately if agreement on the Initial Transfer Price cannot be
reached between the Parties, subject to the cap provided by Article
8.1, or if LICENSEE fails, in any twenty four (24)&nbsp;month period, to
meet the minimum order quantity set forth in Appendix&nbsp;B-1 hereto,
and fails to cure such failure within thirty (30)&nbsp;calendar days of
HAMELN&#146;s written notice. Purchases made by LICENSEE to cure such
failure shall only be counted for the twenty four (24)&nbsp;month period
with a deficit in the minimum order quantity even if made in the
following measurement period.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt"><B>14.5 Effect of Termination</B>




<P align="left" style="margin-left:3%; font-size: 10pt">BY REASON OF THE EXPIRATION, NON-RENEWAL, OR TERMINATION OF THIS
AGREEMENT, EXCEPT FOR ANY TERMINATION BY LICENSEE PURSUANT TO ARTICLE
14.2 (CAUSED BY A BREACH BY HAMELN) OR 14.3 (DUE TO A HAMELN BANKRUPTCY),
HAMELN SHALL NOT BE LIABLE TO LICENSEE FOR COMPENSATION OR REIMBURSEMENT
OF COSTS AND/OR DAMAGES, ON ACCOUNT OF ANY LOSS OF PRESENT OR PROSPECTIVE
PROFITS ON SALES OR ANTICIPATED SALES, ON ACCOUNT OF ANY EXPENDITURES,
INVESTMENTS, INVENTORY, LEASES OR OTHER COMMITMENTS MADE IN CONNECTION
WITH THIS AGREEMENT OR IN THE ANTICIPATION OF EXTENDED PERFORMANCE
HEREUNDER, OR IN CONNECTION WITH THE ESTABLISHMENT, DEVELOPMENT, OR
MAINTENANCE OF LICENSEE&#146;S BUSINESS OR GOODWILL, OR FOR ANY OTHER REASON.


<P align="left" style="font-size: 10pt"><B>15. Rights and Obligations upon Termination</B>



<P align="left" style="font-size: 10pt"><B>15.1 In case of Expiration or Regular Termination</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Upon the regular expiration or termination in accordance with Article
14.1 of this Agreement, all outstanding sums payable by LICENSEE to
HAMELN shall immediately become due and payable. In this event the rights
and licenses in Article&nbsp;2 shall cease as per the date this Agreement is
terminated. Notwithstanding anything to the contrary, upon such
expiration or termination, LICENSEE shall nevertheless be permitted to
sell Products remaining in its inventory in the Territory, on a
non-exclusive basis provided that LICENSEE complies with all other terms
and conditions herein until such Products are sold or otherwise disposed.


<P align="center" style="font-size: 10pt">Page 18 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>15.2 In case of breach by HAMELN</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Upon the justified termination of this Agreement by LICENSEE in
accordance with Article&nbsp;14.2 or 14.3 or an unauthorized termination by
HAMELN, HAMELN shall promptly pay to LICENSEE the amount equal to (Y)
&#128;1,500,000, less (Z) &#128;1,500,000 multiplied by a fraction, the
numerator of which is equal to the number of days elapsed from the
Effective Date, and the denominator of which is the total number of days
in a seven (7)&nbsp;year period. Notwithstanding anything to the contrary,
upon such termination, LICENSEE shall nevertheless be permitted to sell
Products remaining in its inventory in the Territory, on a non-exclusive
basis provided that LICENSEE complies with all other terms and conditions
herein until such Products are sold or otherwise disposed.


<P align="left" style="font-size: 10pt"><B>15.3 In case of breach by LICENSEE</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Upon the justified termination of this Agreement by HAMELN in accordance
with Article&nbsp;14.2, 14.3 or 14.4 above, the rights and licenses in Article
2 shall cease as per the date this Agreement is terminated pursuant to
such Articles. Notwithstanding anything to the contrary, upon such
termination, LICENSEE shall nevertheless be permitted to sell Products
remaining in its inventory in the Territory, on a non-exclusive basis
provided that LICENSEE complies with all other terms and conditions
herein until such Products are sold or otherwise disposed.


<P align="left" style="font-size: 10pt"><B>16. Protection of Licensed Patents</B>



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Product and/or the Active Substance and/or the
manufacturing thereof may be protected by one or more patents or
patent applications in the name of or licensed to HAMELN or any of
its Affiliated Companies.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE obtains information that:</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a Third Party may infringe any of HAMELN&#146;s
Intellectual Property Rights related to the Products in the
Territory, or</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a Third Party intends to file or has filed a
patent application or has obtained a patent which may overlap
with any of HAMELN&#146;s Intellectual Property Rights in the
Territory,</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall promptly notify HAMELN thereof. HAMELN will in its
sole discretion take such steps as necessary to prosecute such
infringement or oppose such conflicting patent application or
patent. If such actions would require the cooperation of LICENSEE,
LICENSEE shall provide HAMELN with all necessary assistance.
HAMELN may reasonably require without charging this to HAMELN
except in respect to external costs incurred which had been
previously agreed in writing by HAMELN.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The expenses incurred in taking such steps as mentioned
under Article&nbsp;16(ii) and any proceeds which may be obtained out of
legal activities against a Third Party infringing HAMELN &#180;s
Intellectual Property Rights related to the Products are, in the
absence of agreement to the contrary, for the sole account of
HAMELN.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt"><B>17.&nbsp;Patent Strategy, Judicial Cost and Legal Fees</B>


<P align="left" style="font-size: 10pt"><B>17.1 Patent Strategy</B>




<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN has developed a patent strategy (&#147;Patent Strategy&#148;) that involves
steps to enable launch of the Product in the respective countries of the
Territory or elsewhere, right upon expiry of the relevant Third Party
Patents. HAMELN&#146;s Patent Strategy


<P align="center" style="font-size: 10pt">Page 19 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="margin-left:3%; font-size: 10pt">focuses on avoiding preliminary injunctions and/or other Third Party
measures meant to prevent or delay launch of the Product in the Territory
and the subsequent sales of the Product. The Patent Strategy is also
aiming at avoiding claims and/or the revoking thereof.


<P align="left" style="font-size: 10pt"><B>17.2 Judicial Cost and Legal Fees</B>




<P align="left" style="margin-left:3%; font-size: 10pt">To the extent that


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE authorizes HAMELN to conduct, execute and control
such Patent Strategy and the related litigation at its sole
discretion and cost, and that</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE agrees to provide HAMELN with all assistance HAMELN
may reasonably require (at HAMELN&#146;s sole expense),</TD>
</TR>

</TABLE>



<P align="left" style="margin-left:3%; font-size: 10pt">any and all external judicial cost and legal fees HAMELN will make either
pro-actively or reactively in view of the Patent Strategy, will be for
the account of HAMELN. In case any damages or compensation of legal cost
are rewarded to any of the Parties by a court of law as a result of
HAMELN&#146;s Patent Strategy, HAMELN will benefit solely.


<P align="left" style="font-size: 10pt"><B>18. Force Majeure</B>




<P align="left" style="margin-left:3%; font-size: 10pt">In the event of any circumstances beyond the control of the Parties
(&#147;Force Majeure&#148;) and in particular, but without prejudice to the
generality of the foregoing, acts of God, fire, explosion, earthquake,
lightning, storm, hurricane, flood, shortage or failure of supply of
materials or equipment from normal sources for manufacture of the
Products, failure of public services, terrorism, war, riots, strikes,
sabotage, accident, embargo or any other action by any government
authority, neither Party shall have any claim, whatsoever, against the
other Party and the Parties further agree that neither will have any
claim against the other for any direct or indirect or consequential loss,
injury or damage which shall include any loss of trade or profit. If
either Party is unable to perform its respective obligations under this
Agreement for a continuous period of ninety (90)&nbsp;days, consecutively or
cumulative during any one (1)&nbsp;year period beginning on the effective date
of this Agreement, by reason of Force Majeure, then the Parties shall
mutually discuss a work-around solution or alternate steps to take to
minimize the impact of such Force Majeure event or other possible courses
of action, including, but not limited to, a mutual agreement to terminate
this Agreement.


<P align="left" style="font-size: 10pt"><B>19. Severability</B>




<P align="left" style="margin-left:3%; font-size: 10pt">If any provision of this Agreement is found by any court or
administrative body of competent jurisdiction to be invalid or
unenforceable, the invalidity or unenforceability of such provision shall
not affect the other provisions of this Agreement, and all provisions not
affected by such invalidity or unenforceability shall remain in full
force and effect. The Party agree to attempt to substitute for any
invalid or unenforceable provision a valid or enforceable provision which
achieves to the greatest extent possible the economic objectives of the
invalid or unenforceable provision.


<P align="left" style="font-size: 10pt"><B>20. Waiver</B>




<P align="left" style="margin-left:3%; font-size: 10pt">The waiver by either Party of a breach of any of the provisions of this
Agreement by the other Party shall not be construed as a waiver of any
succeeding breach of the same or other provisions; nor shall any delay or
omission by either Party in exercising any right that it may have under
this Agreement operate as a waiver of any breach or default by the other
Party.


<P align="center" style="font-size: 10pt">Page 20 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>21. Notices</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Any notice, demand, consent, election, offer, approval, request, or other
communication given under this Agreement shall be in writing and shall be
served personally or delivered by first class, registered or certified,
return receipt requested U.S. mail, postage prepaid. Notices may also be
given by transmittal over electronic transmitting devices such as Telex,
facsimile or telecopy machine, if the Party to whom the notice is being
sent has such a device in its office, provided a complete copy of any
notice so transmitted shall also be mailed in the same manner as required
for a mailed notice. Notices shall be deemed received at the earlier of
actual receipt or three (3)&nbsp;days following deposit in U.S. mail, postage
prepaid. Notices shall be directed to Parties at their addresses as
specified below, provided a Party may change such Party&#146;s address for
notice by giving written notice to the other Party in accordance with
this Article&nbsp;21.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">HAMELN:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LICENSEE:</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">hameln pharmaceuticals gmbh.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Akorn, Inc.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Langes Feld 13
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2500 Millbrook Drive</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">D-31789 Hameln, Germany
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Buffalo Grove, Illinois 60089-4694, USA</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Telefax: &#043;49 5151 581 258
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telefax: &#043;1 847 279-6191</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt"><B>22. Governing Law and Dispute Resolution</B>



<P align="left" style="font-size: 10pt"><B>22.1 Governing Law</B>




<P align="left" style="margin-left:3%; font-size: 10pt">This Agreement is governed by and shall be construed in accordance with
the law of the State of New York, excluding any conflict-of-laws rule or
principle that might refer the governance or the construction of this
Agreement to the law of another jurisdiction.


<P align="left" style="font-size: 10pt"><B>22.2 Dispute Resolution</B>




<P align="left" style="margin-left:3%; font-size: 10pt">The Parties shall, before the commencement of arbitration proceedings,
attempt in good faith to settle their dispute by mediation.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Except as otherwise provided in this Agreement, any dispute,
controversy or claim arising out of or relating to this Agreement,
or any breach thereof, including, without limitation, any claim that
this Agreement, or any part hereof, is invalid, illegal or otherwise
voidable or void, shall be submitted, at the request of any Party,
to binding arbitration by a JAMS&nbsp;ENDISPUTE (&#147;JAMS&#148;) arbitrator, or
such other arbitrator as may be agreed upon by the Parties.
Hearings on such arbitration shall be conducted in New York, New
York. A single arbitrator shall arbitrate any such controversy.
The arbitrator shall hear and determine the controversy in
accordance with applicable law and the intention of the Parties as
expressed in this Agreement, upon the evidence produced at an
arbitration hearing scheduled at the request of either Party. The
arbitrator shall decide all discovery disputes. Judgment on the
award of the arbitrator may be entered in any court having
jurisdiction thereof.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each of the Parties reserves the right to file with a court
of competent jurisdiction an application for temporary or
preliminary injunctive relief, writ of attachment, writ of
possession, temporary protective order and/or appointment of a
receiver on the grounds that the arbitration award to which the
applicant may be entitled may be rendered ineffectual in the absence
of such relief.</TD>
</TR>


</TABLE>

<P align="center" style="font-size: 10pt">Page 21 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any arbitration hereunder may be consolidated by JAMS with
the arbitration of any other dispute arising out of or relating to
the same subject matter when the arbitrator determines that there is
a common issue of law or fact creating the possibility of
conflicting rulings by more than one arbitrator. Any disputes over
which arbitrator or panel of arbitrators shall hear any consolidated
matter shall be resolved by JAMS.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The arbitrator shall not have any power to alter, amend,
modify or change any of the terms of this Agreement nor to grant any
remedy which is either prohibited by the terms of this Agreement, or
not available in a court of law.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All questions in respect of procedure to be followed in
conducting the arbitration as well as the enforceability of this
Agreement to arbitrate which may be resolved by state law shall be
resolved according to the laws of the State of New York.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The costs of the arbitration, including any JAMS
administration fee, the arbitrator&#146;s fee, and costs for the use of
facilities during the hearings, shall be borne equally by the
Parties to the arbitration. Attorneys&#146; fees may be awarded to the
prevailing or most prevailing Party at the discretion of the
arbitrator.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt"><B>23. Miscellaneous</B>



<P align="left" style="font-size: 10pt"><B>23.1 Entire Agreement</B>




<P align="left" style="margin-left:3%; font-size: 10pt">This Agreement constitutes the entire agreement between the Parties with
respect to the subject matter hereto, and supersedes all prior agreements
between the Parties, whether written or oral, relating to the same
subject matter.


<P align="left" style="font-size: 10pt"><B>23.2 Modifications</B>




<P align="left" style="margin-left:3%; font-size: 10pt">No modifications, amendments or supplements to this Agreement shall be
effective for any purpose unless in writing signed by each Party.
Approvals or consents hereunder by a Party shall also be in writing.


<P align="left" style="font-size: 10pt"><B>23.3 Interpretation</B>




<P align="left" style="margin-left:3%; font-size: 10pt">This Agreement is executed in the English language. The language used in
this Agreement shall be deemed to be the language chosen by the Parties
hereto to express their mutual intent and no rule of strict construction
against either Party shall apply to any term or condition of this
Agreement. The headings to this Agreement are for ease of reference only
and shall not be used to construe any provision. The word &#147;including&#148;
shall not limit a more general preceding phrase and the word &#147;hereof&#148;
shall refer to this Agreement as a whole.


<P align="left" style="font-size: 10pt"><B>23.4 Counterparts</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be executed in several counterparts that together
shall be originals and constitute one and the same instrument.


<P align="left" style="font-size: 10pt"><B>23.5 Severability</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any provision of this Agreement, or part thereof, is declared by a
court of competent jurisdiction to be invalid, void or unenforceable,
each and every other provision, or part thereof, shall nevertheless
continue in full force and effect.


<P align="center" style="font-size: 10pt">Page 22 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>23.6 Setoff</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Except as provided in Section&nbsp;12.1, all payments made in connection with
this Agreement are to be made without any setoff. Any attempt by a Party
to setoff amounts against payments owed to the other Party, except as
provided in Section&nbsp;12.1, shall constitute a material breach of this
Agreement pursuant to Article&nbsp;14.2.


<P align="left" style="font-size: 10pt"><B>23.7 Assignments</B>




<P align="left" style="margin-left:3%; font-size: 10pt">Either Party may assign this Agreement or any part thereof upon the prior
written consent of the other Party, which approval shall not be
unreasonably withheld. Any permitted assignee shall resume all
obligations of its assignor under this Agreement. No assignment shall
relieve any Party of responsibility for the performance of any accrued
obligation which such Party then has hereunder.


<P align="left" style="font-size: 10pt"><B>23.8 Interpretation</B>




<P align="left" style="margin-left:3%; font-size: 10pt">The Parties acknowledge and agree that neither this Agreement nor the
other documents executed pursuant hereto shall be construed in favor of
one Party based upon which Party drafted the same, it being acknowledged
that the Parties contributed substantially to the negotiation and
preparation of this Agreement and the other documents executed pursuant
hereto or in connection herewith.


<P align="left" style="font-size: 10pt"><B>23.9 Special Clauses</B>




<P align="left" style="margin-left:3%; font-size: 10pt">The Parties have not agreed, either in writing or orally, on any special
clauses deviating from this Agreement. The General Terms and Conditions
of HAMELN are valid in every instance that is not addressed in this
Agreement. This shall also be valid for forms the Parties use for
business activities, e.g. when placing or confirming separate orders, in
which it is referred to General Terms and Conditions.


<P align="center" style="font-size: 10pt"><B>&#091;signature page follows&#093;</B>



<P align="center" style="font-size: 10pt">Page 23 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF HAMELN and LICENSEE have caused this Agreement to be
executed by their duly authorized representatives on the day and year first set
forth above.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">HAMELN PHARMACEUTICALS GMBH</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">AKORN, INC.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Christoph Kerstein</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Arthur S. Przybyl</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Christoph Kerstein</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Arthur S. Przybyl</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#38; CEO</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Stefan Gliwitzki</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Abu Alam</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Stefan Gliwitzki</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Abu Alam</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Marketing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President, Product and Business <br>Development</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left"></TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">Page 24 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt"><B>Appendix&nbsp;A<BR>
DTPA Business Principles</B>



<P align="left" style="font-size: 10pt">Please see attached.




<P align="center" style="font-size: 10pt">Page 25 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="left" style="font-size: 10pt">1. <B>DTPA Business Principles</B>



<P align="left" style="font-size: 10pt">1.1 <B>Introduction</B>



<P align="left" style="font-size: 10pt">The Marketing Approval for Ca-DTPA and Zn-DTPA was granted to hameln
pharmaceuticals Gmbh (HAMELN)&nbsp;on 11 August&nbsp;2004 by the US FDA. HAMELN
is currently in negotiations with several interested parties which would
like to market the two products in the US. In order to structure these
discussions HAMELN has noted down in this document the main principles
for cooperation with a potential partner in the US.



<P align="left" style="font-size: 10pt">1.2 <B>Exclusive License and Supply Agreement</B>



<P align="left" style="font-size: 10pt">HAMELN is seeking and Exclusive License and Supply Agreement with a
partner who shows the clear potential to successfully introduce the two
products to the US market and who has a clear strategy of how best to
market and sell the products to the various customers in the USA.



<P align="left" style="font-size: 10pt">1.3 <B>License Fee/Term</B>



<P align="left" style="font-size: 10pt">An initial non refundable
minimum License Fee of &#128;1,500,000 (Euro one
Million five-hundred-thousand) is to be paid by the Licensee to HAMELN in
order to receive an Exclusive License to market and sell Ca-DTPA and
Zn-DTPA in the USA for an initial term of 5 (five)&nbsp;years which thereafter
will extend automatically for successive 2 (two)&nbsp;year periods if neither
party has not given notice of termination.



<P align="left" style="font-size: 10pt">1.4 <B>Annual Royalty</B>



<P align="left" style="font-size: 10pt">A non refundable Annual Royalty according to the following post schedule
is to be paid.


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="55%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="73%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2005</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Annual Establishment Fee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">262,200</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Annual Product Fee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">41,710</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">41,710</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Sum in $&nbsp;&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">347,625</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">In Euro</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#128;</TD>
    <TD align="right">288,588</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Regulatory Maintenance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#128;</TD>
    <TD align="right">50,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Grand total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#128;</TD>
    <TD align="right">338,588</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt">The cost will increase annually by approximately 5% to take care of the inflation rate.



<P align="left" style="font-size: 10pt">1.5 <B>Cost for Medical Commitments</B>



<P align="left" style="font-size: 10pt">It is currently estimated
that &#128;450,000 (Euro
four-hundred-fifty-thousand) cost are to be incurred for complying with
the regulatory commitments for post approval studies and Pharmacokinetic
Study for inhalation Therapy. This cost has to be born by the Licensee
as and when it occurs.



<P align="left" style="font-size: 10pt">1.6 <B>Total Product Prices</B>



<P align="left" style="font-size: 10pt">HAMELN will supply the Products to the Licensee at process which
correspond to 50% of the Total (Gross) Sales Price actually achieved in
the market with all purchasing organizations but not less than the
Initial Transfer price.



<P align="left" style="font-size: 10pt">Licensee shall provide HAMELN with summary documentation of all sales
transactions of the Products in the previous quarter not later than the
15th day of the next months after a quarter in order do the final
calculations for the money transferable to HAMELN.




<P align="center" style="font-size: 10pt">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="left" style="font-size: 10pt"><B>* Confidential Treatment Requested Under<BR>
17 C.F.R. &#167;&#167; 200.80(b)(4), 200.83 and 240.24b-2</B>



<P align="left" style="margin-left:3%; font-size: 10pt">1.7 <B>Initial Transfer Price</B>



<P align="left" style="margin-left:3%; font-size: 10pt">The Initial transfer Price for both products will be <B>&#091;...***...&#093;</B>
(<B>&#091;...***...&#093;</B>) for a single pack of 10 ampoules.



<P align="left" style="margin-left:3%; font-size: 10pt">1.8 <B>Annual Minimum Order Quantities</B>

<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN
requests annual minimum order quantities of <B>&#091;...***...&#093; </B>packs of 10 ampoules of either or both products.



<P align="left" style="margin-left:3%; font-size: 10pt">1.9 <B>First Binding Order</B>



<P align="left" style="margin-left:3%; font-size: 10pt">On signing
the final contract a first binding order for <B>&#091;...***...&#093; </B>packs of 10 ampoules of either or both products will be raised by the Licensee.



<P align="left" style="margin-left:3%; font-size: 10pt">2. <B>FURTHER PROCEEDINGS</B>



<P align="left" style="margin-left:3%; font-size: 10pt">We want to assure that first sales can still be achieved in 2004. This
is due to the fact that governmental organizations as well as Individual
hospitals, ambulance services and fire brigades have already approached
us and are demanding for urgent deliveries.



<P align="left" style="margin-left:3%; font-size: 10pt">2.1 <B>Binding Offers</B>



<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN is expecting a binding offer from each interested Party not later
than 11 October&nbsp;2004. These offers should clearly state under which
conditions the Party would like to continue the discussions with HAMELN
and in detail explain by which means what turnover and units could be
sold to the market (marketing strategy/marketing plan).

<P align="left" style="margin-left:3%; font-size: 10pt">HAMELN will review these offers thoroughly by 18 October&nbsp;2004 and take a
decision with which individual interested party to continue the
discussions and to start negotiations.



<P align="left" style="margin-left:3%; font-size: 10pt">2.2 <B>Signing of Term Sheet</B>



<P align="left" style="margin-left:3%; font-size: 10pt">The chosen Party will have to sign a binding Term Sheet guaranteeing her
an exclusive negotiation period for an Exclusive License for the USA
until 30 November&nbsp;2004. By this date a binding contract has to be
signed.



<P align="left" style="margin-left:3%; font-size: 10pt">Upon signing
of the Term Sheet the Party will pay &#128;100,000 (Euro
one-hundred-thousand). Should no agreement for a contract be achieved by
30 November&nbsp;2004 this payment will not be refunded. On signing a final
Exclusive License and Supply Agreement 50% of this payment of &#128;100,000
(i.e. &#128;50,000) will be subtracted from the agreed Initial License Fee.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Offer of Akorn Accepted 12/10/2004
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Agreed to and Accepted By:</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Christoph Kerstein
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Arthur S. Przybyl</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><HR size="1" noshade width="75%" align="left">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade width="75%" align="left"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Christoph Kerstein
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Arthur S. Przybyl</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Managing Director, Hameln Pharmaceuticals<BR>
Gmbh
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and CEO, Akorn, Inc.</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P>
<HR size="1" width="18%" align="left" noshade>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top">
    <TD width="1%" nowrap align="right">*</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">CONFIDENTIAL TREATMENT REQUESTED &#151; This language has been omitted and filed
separately with the Securities &#038; Exchange Commission.</TD>
</TR>

</TABLE>




<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="left" style="font-size: 10pt"><B>* Confidential Treatment Requested Under<BR>
17 C.F.R. &#167;&#167; 200.80(b)(4), 200.83 and 240.24b-2</B>


<P align="center" style="font-size: 10pt"><B>Appendix&nbsp;B-1<BR>
License Fee, Establishment Fee And Quantity</B>



<P align="left" style="font-size: 10pt"><B>License Fee: </B>&#128;1,500,000; provided that &#128;50,000 of the &#128;100,000 paid
by LICENSEE under the DTPA Business Principles shall apply towards the License
Fee yielding a net due amount of &#128;1,450,000.



<P align="left" style="font-size: 10pt"><B>First Binding Order Quantity: &#091;...***...&#093; </B>packs (10 ampoules per packs), in
the aggregate, of Ca-DTPA and ZN-DTPA.



<P align="left" style="font-size: 10pt"><B>Minimum Order Quantity: </B>For each twenty-four (24)&nbsp;calendar month period,
beginning as of the Effective Date, <B>&#091;...***...&#093; </B>packs (10 ampoules per packs),
in the aggregate, of Ca-DTPA and ZN-DTPA. (For the avoidance of doubt, the
above first binding order quantity shall be included in the initial twenty-four
(24)&nbsp;month measurement period.)




<P>
<HR size="1" width="18%" align="left" noshade>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top">
    <TD width="1%" nowrap align="right">*</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">CONFIDENTIAL TREATMENT REQUESTED &#151; This language has been omitted and filed
separately with the Securities &#038; Exchange Commission.</TD>
</TR>

</TABLE>




<P align="center" style="font-size: 10pt">Page 26 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="left" style="font-size: 10pt"><B>* Confidential Treatment Requested Under<BR>
17 C.F.R. &#167;&#167; 200.80(b)(4), 200.83 and 240.24b-2</B>


<P align="center" style="font-size: 10pt"><B>Appendix&nbsp;B-2<BR>
Product List</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="27%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Product /</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Shelf Life</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Bulk Batch</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Initial Transfer Price</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Strength</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Presentation</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>(years)</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Size /Unit</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>(EUR) per Unit</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">10 ampoules</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Ca-DTPA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">per pack</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>&#091;***&#093;</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">10 ampoules</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Zn-DTPA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">per pack</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>&#091;***&#093;</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<p>
<HR noshade size="1" width="25%" align="left">
<DIV align="left" style="font-size: 10pt">*&nbsp;&nbsp;&nbsp;CONFIDENTIAL
TREATMENT REQUESTED - This language has been omitted and filed
separately with the Securities &#038; Exchange Commission.</DIV>
<P align="center" style="font-size: 10pt">Page 27 of 31
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="center" style="font-size: 10pt"><B>Appendix&nbsp;C<BR>
Hameln&#146;s Patents</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Product</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>NDA</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Orphan Drug Designation</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Pentetate Calcium Trisodium</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21749</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">IP</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Pentetate Zinc Trisodium</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21751</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">IP</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">Page 28 of 31
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><B>* Confidential Treatment Requested Under
17 C.F.R. &#167;&#167; 200.80(b)(4), 200.83 and 240.24b-2</B>



<P align="center" style="font-size: 10pt"><B>Appendix&nbsp;D<BR>
Example of Final Product Prices</B>



<P align="left" style="font-size: 10pt"><B>Example for calculation of Final Product Price</B>



<P align="left" style="font-size: 10pt"><B>A given quarter</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>1. Delivery to Akorn</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>2. Sales by Akorn to the market</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Units delivered
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Number of Units invoiced
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Transfer Price per unit
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Total Gross Sales Price
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Invoice to Akorn
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt"><B>3. Formula for calculating Final
Product Price</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top" colspan="10" nowrap><DIV style="margin-left:0px; text-indent:-0px">(Total Gross Sales Price * <B>&#091;...***...&#093;</B>) - (Number of Units invoices *
</DIV></TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top" nowrap colspan="3"><DIV style="margin-left:0px; text-indent:-0px">Initial Transfer Price)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>&#091;...***...&#093;</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">*
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>) - (
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">*
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">assumed echange rate
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1&#128;=
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">$&nbsp;1.20</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>&#091;...***...&#093;</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>*</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap><B>) - (</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>*</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>&#091;...***...&#093;</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">-
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">=</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>&#091;...***...&#093;</B></TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="4" noshade>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="33%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="52%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>4. At the end of this Quarter Akorn has
to pay</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;...***...&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>to hameln according to the &#147;Final Product Price&#148; calculation.</B></TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt"><HR size="1" noshade width="30%" align="left">



<P align="left" style="font-size: 10pt">* CONFIDENTIAL TREATMENT REQUESTED &#151; This language has been omitted and filed
separately with the Securities &#038; Exchange Commission.




<P align="center" style="font-size: 10pt">
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
